LDS/Medical Tests/Oncomine™ Dx Target Test for Non–Small Cell Lung Cancer (NSCLC) and Other Cancer Treatment Monitoring

Oncomine™ Dx Target Test for Non–Small Cell Lung Cancer (NSCLC) and Other Cancer Treatment Monitoring

The Oncomine™ Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high-throughput, parallel-sequencing technology to detect single nucleotide variants (SNVs), deletions, and insertions in 23 genes from DNA and fusions in ROS1 and RET from RNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from patients with non-small cell lung cancer (NSCLC), IDH1 SNVs from FFPE tumor tissue samples from patients with cholangiocarcinoma (CC), BRAF V600E mutations from FFPE tumor tissue samples from patients with anaplastic thyroid cancer (ATC), IDH1and IDH2 SNVs from FFPE tumor tissue samples from patients with astrocytoma (AC) or oligodendroglioma (OG), RET SNVs, multi-nucleotide variants (MNVs), and deletions from DNA isolated from FFPE tumor tissue samples from patients with medullary thyroid cancer (MTC), and RET fusions from RNA isolated from FFPE tumor tissue samples from patients with thyroid cancer (TC) using the Ion PGM™ Dx System.

The test is indicated as a companion diagnostic to aid in selecting NSCLC, CC, ATC, AC, OG, MTC, and TC patients for treatment with the targeted therapies as shown below and in accordance with the approved therapeutic product labeling.

    Tissue Type	Gene	       Variant	                Targeted Therapy
  • NSCLC BRAF BRAF V600E mutations TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)
  • NSCLC EGFR EGFR L858R mutation, EGFR exon 19 deletions IRESSA® (gefitinib)
  • NSCLC EGFR EGFR exon 20 insertions RYBREVANT™ (amivantamab-vmjw)
  • NSCLC ERBB2/HER2 ERBB2/HER2 activating mutations (SNVs and exon 20 insertions) ENHERTU® (fam-trastuzumab deruxtecan-nxki)
  • NSCLC RET RET fusions GAVRETO™ (pralsetinib), RETEVMO® (selpercatinib)
  • NSCLC ROS1 ROS1 fusions XALKORI® (crizotinib)
  • CC IDH1 IDH1 R132C, R132G, R132H, R132L, R132S mutations TIBSOVO® (ivosidenib)
  • ATC BRAF BRAF V600E mutations TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)
  • MTC RET RET mutations (SNVs, MNVs, deletions) RETEVMO® (selpercatinib)
  • TC RET RET fusions RETEVMO® (selpercatinib)
  • AC and OG IDH1, IDH2 IDH1 R132C/G/H/L/S, IDH2 R172M/K/W/S/G mutations VORANIGO® (vorasidenib)
  • Companion diagnostic test for therapy selection and monitoring for non-small cell lung cancer
  • Companion diagnostic test for therapy selection and monitoring of cholangiocarcinoma (CC)
  • Companion diagnostic test for therapy selection and monitoring anaplastic and medullary thyroid cancer
  • Companion diagnostic test for therapy selection and monitoring astrocytoma or oligodendroglioma
  • Positive: any pathogenic variants detected in 23-targeted genes amenable to targeted therapies
  • Negative: No pathogenic variants detected. Gene targeted therapy is not indicated

No pathogenic variants (mutations) detected

Next generation sequencing (NGS).

Formalin-fixed paraffin embedded (FFPE) tumor tissue specimens.

Storage

  • FFPE is stable at ambient for longer time. 
Lung biopsy/fine needle aspiration, liquid biopsy or ctDNA, fluorescent in situ hybridization.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login